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Abstract 
Background: Guidelines have classified patients with acute coronary syndrome (ACS) and diabetes as a special 
population, with specific sections presented for the management of these patients considering their extremely high 
risk. However, in China up-to-date information is lacking regarding the burden of diabetes in patients with ACS and 
the potential impact of diabetes status on the in-hospital outcomes of these patients. This study aims to provide 
updated estimation for the burden of diabetes in patients with ACS in China and to evaluate whether diabetes is still 
associated with excess risks of early mortality and major adverse cardiovascular and cerebrovascular events (MACCE) 
for ACS patients.
Methods: The Improving Care for Cardiovascular Disease in China-ACS Project was a collaborative study of the Amer-
ican Heart Association and the Chinese Society of Cardiology. A total of 63,450 inpatients with a definitive diagnosis 
of ACS were included. Prevalence of diabetes was evaluated in the overall study population and subgroups. Multivari-
ate logistic regression was performed to examine the association between diabetes and in-hospital outcomes, and a 
propensity-score-matched analysis was further conducted.
Results: Among these ACS patients, 23,880 (37.6%) had diabetes/possible diabetes. Both STEMI and NSTE-ACS 
patients had a high prevalence of diabetes/possible diabetes (36.8% versus 39.0%). The prevalence of diabetes/possi-
ble diabetes was higher in women (45.0% versus 35.2%, p < 0.001). Even in patients younger than 45 years, 26.9% had 
diabetes/possible diabetes. While receiving comparable treatments for ACS, diabetes/possible diabetes was associ-
ated with a twofold higher risk of all-cause death (adjusted odds ratio 2.04 [95% confidence interval 1.78–2.33]) and a 
1.5-fold higher risk of MACCE (adjusted odds ratio 1.54 [95% confidence interval 1.39–1.72]).
Conclusions: Diabetes was highly prevalent in patients with ACS in China. Considerable excess risks for early mortal-
ity and major adverse cardiovascular events were found in these patients.
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Background
Patients with both clinical cardiovascular disease (CVD) 
and diabetes were classified as extreme-risk groups in 
recently published guidelines issued by the American 
Association of Clinical Endocrinologists and the Ameri-
can College of Endocrinology [1]. The latest guidelines 
for ST-segment elevation myocardial infarction (STEMI) 
and non-ST-segment elevation acute coronary syndrome 
(NSTE-ACS) also classified patients with acute coronary 
syndrome (ACS) and diabetes as a special population and 
presented specific sections for the management of these 
patients in consideration of their extremely high risk 
[2–5]. However, limited studies have been conducted to 
evaluate the burden of diabetes on ACS patients in China 
in recent years. The latest studies to focus on the preva-
lence of diabetes were conducted more than 10 years ago 
[6, 7]. With the rapid increase in the prevalence of diabe-
tes among the general population in China, the burden 
of diabetes among Chinese ACS patients needs to be re-
evaluated. In addition, despite the advancements in the 
clinical management and the wide application of percu-
taneous coronary intervention (PCI) in the past decade, 
whether the excess risk caused by diabetes is reduced 
among ACS has remained unclear. Therefore, an up-to-
date evaluation regarding the prevalence of diabetes in 
ACS patients in China and the potential impact of diabe-
tes status on the outcomes of these patients during hospi-
talization is needed.
In this study, we aim to provide an updated estimation 
of the burden of diabetes in patients with ACS and to 
evaluate whether diabetes is still associated with excess 
risks for in-hospital all-cause death or major adverse 
cardiovascular and cerebrovascular events (MACCE) to 
these patients in China, based on the Improving Care for 
Cardiovascular Disease in China-ACS Project (CCC-ACS 
Project), a large nationwide registry and quality improve-
ment study.
Research design and methods
Study design and population
The CCC-ACS project, a nationwide registry and quality 
improvement study with an ongoing database focusing 
on quality of ACS care, was launched in 2014 as a col-
laborative initiative of the American Heart Association 
and the Chinese Society of Cardiology. In Phases I and II 
of the project, only the tertiary hospitals were included, 
150 centers representing the diversity of care for ACS in 
tertiary hospitals across China. Since July 2017, Phase III 
of the project has extended into secondary hospitals. The 
data for this study are based on Phases I and II of the pro-
ject. Details of the design and methodology of the CCC 
project have been published [8]. A standard web-based 
data collection platform (Oracle Clinical Remote Data 
Capture, Oracle) was used in this study. Trained data 
abstractors in the participating hospitals reported the 
required data, which they abstracted from the patients’ 
original medical records. Eligible patients were consecu-
tively reported to the CCC-ACS database for each month 
before the middle of the following month. Third-party 
clinical research associates performed quality audits to 
ensure that cases were reported consecutively rather than 
selectively. In addition, about 5% of reported cases were 
randomly selected, and the reported information was 
compared with the original medical records as a quality 
assessment and a method to promote accuracy and com-
pleteness of the reported data. According to the quality 
audit reports, the data in this study were appropriately 
reported with an accuracy rate greater than 95%.
Based on principal discharge diagnosis, 63,641 inpa-
tients with ACS were registered between November 
2014 and June 2017 from 150 hospitals. Of these, 63,450 
inpatients were included in this study after excluding 191 
(0.3%) patients with incomplete demographic informa-
tion. The flow chart for study population recruitment can 
be found in Additional file 1: Figure S1.
Definition of diabetes
Diabetes was defined according to one of the following 
criteria: (1) a self-reported diabetes which was previously 
diagnosed by physicians or use of glucose-lowering drugs 
before hospitalization; (2) diabetes listed in the medical 
records as the secondary discharge diagnosis; (3) glycated 
hemoglobin A1c (HbA1c) concentration ≥ 6.5%.
Possible diabetes was defined in ACS patients with level 
of fasting blood glucose (FBG) ≥ 7.0  mmol/L but with-
out measurement of HbA1c, as we could not distinguish 
between undiagnosed diabetes and stress hyperglycemia 
in this group of patients by the results of FBG alone.
Definition of in‑hospital outcomes
The outcomes of this study included all-cause deaths and 
MACCEs that occurred during hospitalization. MACCEs 
were defined as a combination of cardiac death, recur-
rent myocardial infarction, stent thrombosis, and stroke. 
Trial registration NCT02306616. Registered December 3, 2014
Keywords: Acute coronary syndrome, Diabetes, Prevalence, Epidemiology, Death, MACCE, In-hospital outcome, CCC-
ACS
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All of these outcomes were diagnosed by doctors during 
patients’ hospitalization and recorded in medical records.
Definition of other variables
Hypertension was defined as having a history of hyper-
tension, receiving antihypertensive therapy, or systolic 
blood pressure (SBP) ≥ 140  mmHg or diastolic blood 
pressure (DBP) ≥ 90  mmHg at admission. Elevated low-
density lipoprotein cholesterol (LDL-C) was defined 
as serum LDL-C ≥ 1.8  mmol/L (70  mg/dL). Low high-
density lipoprotein cholesterol (HDL-C) was defined as 
serum HDL-C < 1.0  mmol/L (40  mg/dL). Elevated tri-
glyceride (TG) was defined as serum TG ≥ 2.3  mmol/L 
(200 mg/dL). Current smoking was defined as smoking in 
the preceding 1 year according to the medical records of 
the patients. Estimated glomerular filtration rate (eGFR) 
was calculated by the equation developed by the Chronic 
Kidney Disease Epidemiology Collaboration [9]. A his-
tory of coronary heart disease (CHD) was specified if 
the patients had a clinical history of myocardial infarc-
tion or underwent PCI or coronary artery bypass graft-
ing (CABG) before the current hospitalization. Other 
clinical history of diseases, including cerebrovascular dis-
ease, heart failure, peripheral artery disease (PAD), atrial 
fibrillation, and renal failure was defined according to the 
notes on original medical records. Heart failure, cardiac 
arrest, and cardiac shock occurring within 24  h of the 
current admission were defined as a severe clinical condi-
tion. The definition of fivefold elevated myocardial injury 
markers was elevation of cardiac injury marker beyond 
fivefold the upper reference limit [5]. In addition, we eval-
uated the risk of in-hospital death using the Global Reg-
istry of Acute Coronary Events (GRACE) score whereby 
patients with a score greater than 140 were classified as 
high risk [10]. Subtypes of ACS were defined based on 
the principal discharge diagnosis of medical records. 
Patients with a diagnosis of non-STEMI and unstable 
angina were classified as NSTE-ACS. Cardiologists diag-
nosed patients based on guidelines of STEMI and NSTE-
ACS issued by the Chinese Society of Cardiology [11, 12]. 
The diagnostic criteria included symptoms of chest pain, 
results of ECG, and biomarkers of myocardial injury.
Statistical analysis
As most of the patients with possible diabetes could be 
undiagnosed or were at high risk of developing diabe-
tes, and needed the same care as diabetic patients dur-
ing hospitalization [2–5, 13], for the purposes of this 
study we combined diabetes and possible diabetes for 
analysis. Prevalence of diabetes/possible diabetes and 
its 95% confidence intervals (CIs) were estimated in 
the overall study population and in subgroups by sex, 
age groups, and CHD history. The characteristics, 
in-hospital treatments, and in-hospital outcomes of 
these patients were described and compared according 
to diabetic status in ACS patients. Continuous vari-
ables with normal distribution were shown as mean 
(standard deviation [SD]) and differences between 
groups were compared using t-tests; continuous vari-
ables with skewed distribution were shown as median 
(interquartile range [IQR]) and compared using the 
Mann–Whitney U test; and categorical variables were 
presented as the number (percentage) and compared 
using chi-square test. Logistic multivariable regression 
analysis was carried out to examine the association 
between diabetes/possible diabetes and in-hospital 
outcomes. Univariate analysis was performed first, 
followed by multivariate-adjusted analysis. The can-
didate adjusted factors are confounding factors that 
either have been included in the risk assessment or 
have been reported more than once with an effect on 
death or MACCE, including baseline characteristics, 
risk factors, medical history, clinical conditions at 
admission, and treatment during hospitalization, i.e., 
age (continuous), sex (male/female), current smoking 
(yes/no), SBP levels (continuous), heart rate (continu-
ous), cardiac arrest at admission (yes/no), Killip class 
at admission (class I/II–III/IV), history of CHD (yes/
no), cerebrovascular disease (yes/no), PAD (yes/no), 
heart failure (yes/no), renal failure (yes/no), eGFR 
(continuous), administration of dual antiplatelet ther-
apy (yes/no), anticoagulant therapy (yes/no), statins 
(yes/no), β-blockers (yes/no), and angiotensin-con-
verting enzyme inhibitors (ACEIs)/angiotensin-recep-
tor blockers (ARBs) (yes/no) during hospitalization, 
PCI treatment (yes/no), fivefold elevated myocardial 
injury markers (yes/no), type of ACS (STEMI/NSTE-
ACS), and whether patients were transferred from 
another hospital before the current hospitalization 
(yes/no). After forward stepwise selection with entry 
and exit criteria both set at the p = 0.15 level, the vari-
ables listed in the legend of Table  4 were eventually 
included in the multivariable adjusted logistic model 
of all-cause death and MACCE, respectively. Given the 
differences in pathologies, management, and progno-
sis of STEMI and NSTE-ACS, we performed the above 
analyses in these two subtypes of ACS patients.
Since some ACS patients with FBG ≥ 7.0  mmol/L but 
with HbA1c < 6.5% were classified as patients without 
diabetes, who could mostly be diagnosed with stress 
hyperglycemia and associated with increased risk of 
death and MACCE, we conducted a sensitivity analysis 
by excluding these patients and recalculated the risk of 
diabetes/possible diabetes.
Subgroup analysis, including age, sex, Killip class, 
eGFR, GRACE score, PCI treatment, types of ACS, 
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and whether the patient was transferred before the 
current hospitalization, was performed by using 
important characteristics in a multivariable adjusted 
logistic regression model. Odds ratios (ORs) between 
subgroups were compared using a Z-test [14].
In addition, we conducted a propensity-score-
matched analysis to further confirm the association 
between diabetes/possible diabetes and in-hospital 
outcomes. First, a propensity score of having diabetes/
possible diabetes was calculated by a logistic regres-
sion model with the variables age, sex, SBP levels, heart 
rate, LDL-C, HDL-C, TG, eGFR, Killip class at admis-
sion, history of myocardial infarction, PCI, CABG, 
cerebrovascular disease, heart failure, PAD, atrial 
fibrillation, renal failure, and type of ACS. Patients 
with and without diabetes/possible diabetes were then 
matched at a 1:1 ratio by propensity score using near-
est-neighbor matching without replacement, with a 
caliper of 0.02. The absolute standardized differences 
of variables included for the calculation of propensity 
score were compared before and after propensity-score 
matching. Standardized differences < 10.0% for these 
included variables indicated a relatively small imbal-
ance. The baseline characteristics and in-hospital man-
agement between the two propensity-score-matched 
subsets were re-compared. As some characteristics did 
not exactly match between the two groups even after 
the propensity-score matching, multivariable logistic 
regression was further performed to compare the risk 
by adjusting factors eventually included in the whole 
study population by stepwise selection.
Statistical analyses were performed using SAS 9.4 
(SAS Institute, Cary, NC, USA) and Stata 14.0 (Stata, 
College Station, TX, USA). Two-tailed p values of less 
than 0.05 were considered statistically significant.
Results
Prevalence of diabetes in ACS patients
The average age of the 63,450 ACS patients, 25.1% of 
whom were female, was 62.9 (± 12.4) years. Among these 
patients, a total of 23,880 (37.6%) had diabetes/possible 
diabetes (Table  1), including 29.7% diabetes and 7.9% 
possible diabetes. Both STEMI and NSTE-ACS patients 
had a high prevalence of diabetes/possible diabetes, but 
prevalence was slightly higher in patients with NSTE-
ACS than in those with STEMI (39.0% versus 36.8%). 
Women had a higher proportion of diabetes/possible 
diabetes than men (45.0% versus 35.2%). The prevalence 
of diabetes/possible diabetes increased significantly with 
age. However, even in patients younger than 45  years, 
26.9% of them had diabetes/possible diabetes. Patients 
with a history of CHD had a higher prevalence of dia-
betes/possible diabetes than those without CHD history 
(45.9% versus 36.6%).
Characteristics of ACS patients with diabetes
Compared with ACS patients without diabetes, patients 
with diabetes/possible diabetes had a higher frequency 
of previous diseases and major cardiovascular risk fac-
tors (Table 2). Of these ACS patients with diabetes/pos-
sible diabetes, 21.5% had previously diagnosed CVD and 
51.2% had three or more other cardiovascular risk fac-
tors, including hypertension, different types of dyslipi-
demia, and smoking.
ACS patients with diabetes/possible diabetes also had 
more severe clinical conditions than those without dia-
betes at admission, with a higher frequency of heart 
failure (11.9% versus 7.2%), cardiac shock (3.7% versus 
2.7%), and cardiac arrest (2.2% versus 1.8%). In addition, 
the proportion of high-risk patients based on GRACE 
scores was also significantly higher in patients with 
Table 1 Prevalence of diabetes/possible diabetes in patients with ACS
CHD coronary heart disease, ACS acute coronary syndrome, STEMI ST-segment elevation myocardial infarction, NSTE-ACS non-ST-segment elevation acute coronary 
syndrome
Total ACS (N = 63,450) STEMI (N = 39,793) NSTE‑ACS (N = 23,657)
Total, n (% [95% CI]) 23,880 (37.6 [37.3–38.0]) 14,650 (36.8 [36.3–37.3]) 9230 (39.0 [38.4–39.6])
Sex, n (% [95% CI])
 Male 16,721 (35.2 [34.8–35.6]) 10,746 (34.5 [34.0–35.0]) 5975 (36.5 [35.7–37.2])
 Female 7159 (45.0 [44.2–45.7]) 3904 (45.1 [44.1–46.2]) 3255 (44.7 [43.6–45.9])
Age, n (% [95% CI]) (years)
 < 45 1281 (26.9 [25.6–28.1]) 1003 (27.5 [26.1–29.0]) 278 (24.7 [22.2–27.2])
 45–64 10,726 (36.2 [35.6–36.7]) 7041 (36.1 [35.4–36.8]) 3685 (36.2 [35.3–37.2])
 ≥ 65 11,873 (40.9 [40.4-41.5]) 6606 (39.7 [38.9-40.4]) 5267 (42.6 [41.8–43.5])
CHD history, n (% [95% CI])
 Yes 3197 (45.9 [44.7–47.1]) 1186 (44.3 [42.4–46.2]) 1186 (44.3 [42.4–46.2])
 No 20,683 (36.6 [36.2–37.0]) 13,464 (36.3 [35.8–36.8]) 7219 (37.3 [36.6–38.0])
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diabetes/possible diabetes in comparison with non-dia-
betic patients (39.2% versus 31.2%). Similar results were 
observed in subtypes of ACS patients with and without 
diabetes/possible diabetes.
In‑hospital management of ACS patients with diabetes
We compared the treatments for ACS between patients 
with and without diabetes/possible diabetes with 
regard to STEMI and NSTE-ACS (Table 3). Most of the 
received treatments, including PCI, antiplatelet therapy, 
anticoagulant therapy, statins, and β-blockers, were 
comparable between patients with and without diabe-
tes/possible diabetes. We did not observe a higher rate 
of CABG in ACS patients with diabetes in this study.
In‑hospital outcomes of ACS patients with diabetes
The in-hospital outcomes were compared between ACS 
patients with and without diabetes/possible diabetes 
(Fig.  1 and Additional file  1: Table  S1). Higher rates of 
all-cause death and MACCE were observed in all ACS 
patients with diabetes/possible diabetes as well as in 
the subtypes of ACS. In univariate logistic regression 
analysis, a significantly higher risk of all-cause death and 
MACCE was observed in patients with diabetes/possi-
ble diabetes (Table  4). The independent association was 
further evaluated using multivariable analyses (Table  4 
and Additional file 1: Tables S2 and S3). After multivari-
able adjustment, diabetes/possible diabetes was associ-
ated with a twofold increased risk of all-cause death (OR, 
Table 3 In-hospital management of ACS patients with diabetes/possible diabetes
STEMI ST-segment elevation myocardial infarction, NSTE-ACS non-ST-segment elevation acute coronary syndrome, DAPT dual antiplatelet therapy, UFH unfractionated 
heparin, LMWH low molecular weight heparin, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting
The usage rate of drugs was calculated in patients without drug contraindications
a  Time of PCI, time from admission to PCI, and detailed data of time of PCI were not available for 8600 patients with PCI
b  Type of stents and type of PCI were not available for 849 patients with stent implantation
STEMI NSTE‑ACS
Diabetes/
possible diabetes 
(N = 14,650)
No diabetes (N = 25,143) p value Diabetes/
possible diabetes 
(N = 9230)
No diabetes (N = 14,427) p value
DAPT, % (n/N) 95.4 (13,911/14,577) 95.5 (23,915/25,037) 0.686 89.4 (8130/9098) 90.0 (12,827/14,250) 0.108
 Aspirin, % (n/N) 96.3 (14,032/14,579) 96.5 (24,163/25,038) 0.184 93.1 (8469/9100) 93.6 (13,343/14,253) 0.099
 P2Y12 inhibitors, % (n/N) 96.9 (14,194/14,643) 96.7 (24,295/25,135) 0.134 92.7 (8534/9211) 92.9 (13,394/14,411) 0.395
GPIIb/IIIa, % (n/N) 39.8 (5816/14,625) 38.4 (9651/25,112) 0.008 17.5 (1612/9196) 17.3 (2494/14,406) 0.668
Anticoagulant, % (n/N) 79.4 (11,632/14,643) 79.2 (19,912/25,135) 0.606 68.1 (6273/9211) 67.1 (9668/14,411) 0.104
 UFH 5.3 (768/14,623) 4.5 (1121/25,097) < 0.001 2.0 (185/9171) 1.9 (271/14,379) 0.472
 LMWH 73.0 (10,676/14,623) 73.7 (18,490/25,097) 0.147 62.8 (5760/9171) 62.4 (8969/14,379) 0.505
 Fondaparinux sodium 1.3 (186/14,623) 1.0 (262/25,097) 0.038 2.2 (201/9171) 1.6 (232/14,379) 0.001
 Other anticoagulants 1.9 (280/14,623) 2.0 (512/25,097) 0.389 2.0 (185/9171) 2.0 (280/14,379) 0.707
Statins, % (n/N) 94.1(37,382/39,735) 94.0 (13,748/14,628) 0.544 92.9 (8562/9212) 93.4 (13,459/14,408) 0.161
Beta-blockers, % (n/N) 64.3 (2917/4536) 62.5 (4998/7997) 0.044 67.6 (2046/3028) 66.4 (3431/5164) 0.295
ACEI/ARB, % (n/N) 49.8 (6687/13,427) 48.4 (11,151/23,030) 0.011 54.0 (4643/8606) 48.8 (6535/13,396) < 0.001
PCI, % (n/N) 77.1 (11,289/14,650) 77.5 (19,484/25,143) < 0.001 58.2 (5367/9230) 61.1 (8810/14,427) 0.006
 Time of  PCIa, % (n/N) (h) < 0.001 0.006
  < 2 55.2 (8574/15,526) 57.4 (5220/9100) 10.0 (734/7341) 8.9 (388/4383)
  2–11.9 10.2 (1577/15,526) 11.5 (1046/9100) 10.0 (731/7341) 10.8 (474/4383)
  12–23.9 3.2 (493/15,526) 3.4 (313/9100) 7.8 (572/7341) 7.2 (314/4383)
  24–71.9 9.8 (1524/15,526) 8.9 (809/9100) 31.2 (2293/7341) 29.5 (1294/4383)
  ≥ 72 21.6 (3358/15,526) 18.8 (1712/9100) 41.0 (3011/7341) 43.7 (1913/4383)
 Type of  stentsb, % (n/N) 0.010 0.088
  Drug eluting stent 98.1 (9827/10,017) 98.1 (16,825/17,145) 96.9 (4317/4456) 96.7 (6997/7235)
  Bare metal stent 1.0 (101/10,017) 1.2 (213/17,145) 1.8 (82/4456) 1.6 (113/7235)
  Other 0.9 (89/10,017) 0.6 (107/17,145) 1.3 (57/4456) 1.7 (125/7235)
CABG, % (n/N) 0.5 (46/10,121) 0.5 (94/17,328) 0.324 0.7 (33/4670) 0.7 (51/7583) 0.824
Length of stay, median 
(IQR), day
10.0 (7.0–13.0) 10.0 (7.0–13.0) < 0.001 10.0 (7.0–13.0) 9.0 (7.0–12.0) < 0.001
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2.04 [95% CI 1.78–2.33]) and a 1.5-fold increased risk of 
MACCE (OR, 1.54 [95% CI 1.39–1.72]). 
We then conducted a sensitivity analysis to evaluate 
the risk of diabetes/possible diabetes. After excluding 
patients with possible stress hyperglycemia (n = 2465) in 
patients without diabetes, diabetes/possible diabetes was 
still associated with an increased risk of in-hospital all-
cause death (OR, 2.22 [95% CI 1.92–2.56]) and MACCE 
(OR, 1.63 [95% CI 1.46–1.83]).
Subgroup analyses were performed based on impor-
tant baseline characteristics. Diabetes/possible diabetes 
was associated with increased risk of all-cause death and 
MACCE in all subgroups (Fig. 2).
In addition, we conducted a propensity-score-matched 
analysis to further confirm the association between dia-
betes/possible diabetes and in-hospital outcomes. After 
propensity-score matching, 19,315 ACS patients with 
diabetes/possible diabetes were matched with 19,315 
patients without diabetes (patients with possible stress 
hyperglycemia were excluded before matching). After 
matching, the standardized differences were less than 
10.0% for all variables included for the calculation of 
propensity score, indicating that ACS patients with and 
without diabetes/possible diabetes were well matched 
(Additional file  1: Figure S2). The characteristics and 
in-hospital treatment between these two groups were 
re-compared, whereby most of the characteristics were 
comparable (Additional file 1: Table S4). The rates of all-
cause death and MACCE remained higher in patients 
with diabetes/possible diabetes, and an excess risk of 
in-hospital outcomes independently associated with dia-
betes/possible diabetes was also found (all-cause death: 
OR, 2.21 [95% CI 1.83–2.66]; MACCE: OR, 1.58 [95% CI 
1.38–1.82]) (Fig. 1 and Table 4).
Discussion
In this study, we provided an updated estimation of the 
burden of diabetes in ACS patients in China and evalu-
ated whether diabetes was independently associated with 
excess risks for in-hospital all-cause death and MACCE 
to these patients, based on a nationally representative 
registry study with a large sample.
Heavy burden of diabetes among ACS patients
We found that 1 in 3 male ACS patients and 2 in 5 
female ACS patients had diabetes/possible diabetes. 
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Subgroup Events/total number OR (95% CI) p for interaction
Age
<75 years 551/47505 1.88 (1.56-2.27)
0.288
≥75 years 510/11608 2.19 (1.79-2.67)
Sex
Men 661/44411 1.99 (1.68-2.37)
0.715
Women 400/14702 2.10 (1.67-2.64)
eGFR
≥90 ml/min/1.73m2 149/27532 1.56 (1.11-2.18)
0.100
<90 ml/min/1.73m2 912/31581 2.12 (1.83-2.47)
Killip class
Killip I 323/40922 1.93 (1.54-2.42)
0.496
Killip II-IV 738/18191 2.13 (1.80-2.52)
GRACE Score
<140 174/36550 1.88 (1.39-2.55)
0.736
≥140 858/19126 1.99 (1.71-2.33)
PCI
Yes 399/42358 1.92 (1.55-2.39)
0.503
No 662/16755 2.12 (1.77-2.53)
Referral status
With referral 393/26860 1.83 (1.47-2.27)
0.209
Without Referral 668/32253 2.19 (1.84-2.62)
0.25 0.50 1.00 2.00 4.00
a
Subgroup Events/total number OR (95% CI) p for interaction
Age
<75 years 917/47505 1.52 (1.32-1.75)
0.702
≥75 years 658/11608 1.59 (1.34-1.88)
Sex
Men 1024/44411 1.47 (1.29-1.68)
0.264
Women 551/14702 1.68 (1.39-2.03)
eGFR
≥90 ml/min/1.73m2 344/27532 1.23 (0.98-1.53)
0.022
<90 ml/min/1.73m2 1231/31581 1.65 (1.46-1.87)
Killip class
Killip I 626/40922 1.47 (1.25-1.73)
0.358
Killip II-IV 949/18191 1.63 (1.41-1.88)
GRACE Score
<140 416/36550 1.56 (1.28-1.90)
0.864
≥140 1104/19126 1.52 (1.33-1.74)
PCI
Yes 708/42358 1.34 (1.15-1.57)
0.014
No 867/16755 1.76 (1.52-2.05)
Referral status
With referral 597/26860 1.83 (1.47-2.27)
0.386
Without Referral 978/32253 2.19 (1.84-2.62)
b
0.50 1.00 2.00 4.00
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Fig. 2 Subgroup analysis for the association between diabetes/possible diabetes and in-hospital outcomes. a Association between diabetes/
possible diabetes and all-cause death during hospitalization. b Association between diabetes/possible diabetes and MACCE during hospitalization. 
OR odds ratio, eGFR estimated glomerular filtration rate, GRACE Global Registry of Acute Coronary Events, PCI percutaneous coronary intervention, 
ACS acute coronary syndrome, STEMI ST-segment elevation myocardial infarction, NSTE-ACS non-ST-segment elevation acute coronary syndrome, 
MACCE major adverse cardiovascular and cerebrovascular events
With the rapid increase in prevalence of diabetes in 
China, the proportion of diabetes in the ACS patients 
will continue to rise [15]. The China Heart Study pub-
lished in 2006 reported that 37.4% of patients with 
acute coronary artery disease were diagnosed with 
diabetes by medical history and FBG [7], and 17.4% 
of these patients were further diagnosed with diabetes 
by oral glucose tolerance test (OGTT). In this situa-
tion, the prevalence of diabetes in ACS patients may be 
higher than the current prevalence reported herein, as 
some patients with diabetes may not have been iden-
tified because OGTT currently is not applied in the 
routine clinical workup to assess the diabetic status 
of patients. These findings indicate that cardiologists 
in China have to manage a large proportion of ACS 
patients with diabetes in their clinical care.
However, there remains some doubt about whether 
our cardiologists are fully prepared to manage this 
group of patients. In this study, we found that 68.2% of 
patients (with both measurement of FBG and HbA1c) 
with FBG ≥ 7.0 mmol/L could be diagnosed with diabetes 
by HbA1c, which meant that about 70% of patients with 
possible diabetes could be diagnosed with diabetes with 
HbA1c tests; however, 57.0% patients did not receive a 
test for HbA1c during hospitalization. Therefore, for a 
considerable number of patients the best opportunity to 
identify and treat their previously undiagnosed diabetes 
might have been missed, particularly for those patients 
with little or no routine health care before the occurrence 
of ACS events. Effectively identifying these patients dur-
ing hospitalization is thus the first key step in cardiolo-
gists’ management strategy. In addition, diabetes also has 
a great impact on the prognosis of various diseases, and 
long-term monitoring is necessary [16–18].
Worse in‑hospital outcomes of ACS patients with diabetes
Our study showed that ACS patients with diabetes/pos-
sible diabetes had a substantially high risk for in-hospi-
tal outcomes compared with patients without diabetes, 
namely a twofold increased risk of all-cause death and a 
1.5-fold increased risk of MACCE. A recently published 
systematic review and meta-analysis provided a summa-
rized excess risk of early mortality from diabetes status 
in patients with myocardial infarction/ACS based on 86 
studies published from 1970 to 2011 [19]. Here it was 
reported that diabetes was associated with a 1.7-fold 
higher risk of early mortality and that the relative risk of 
early death associated with diabetes did not change over 
time [19]. Compared with previous studies in Chinese 
ACS patients, the rates of all-cause death and MACCE 
during hospitalization have been significantly decreased 
in our study [20–22]. These findings might suggest that 
the advancements in the management of ACS patients 
during the last decades have improved the prognosis of 
ACS patients but have not led to a reduction of the risk 
gap between diabetic and non-diabetic patients.
However, one point worth noting is that most of the 
previous studies did not address the problem of undi-
agnosed diabetes and stress hyperglycemia [23, 24], 
which has been defined as possible diabetes in our 
study. Researchers compared patients with history 
(previously diagnosed) of diabetes and those without 
history of diabetes, which included all patients with-
out diabetes, with undiagnosed diabetes, or with stress 
hyperglycemia. These analyses may underestimate the 
relative risks of diabetes given the increased risk of the 
reference group. In our study, we classified patients 
with undiagnosed diabetes and stress hyperglyce-
mia (FBG ≥ 7  mmol/L) as possible diabetes as they 
did not have an HbA1c result, and who were associ-
ated with a threefold increased risk of all-cause death 
compared with those without diabetes. Therefore, all 
ACS patients with FBG ≥ 7  mmol/L or with diabetes 
should raise major concern in clinical practice in light 
of their extremely high risk. Relative hyperglycemia, 
a new concept, reported to associated with complica-
tions following an acute myocardial infarction [25], 
also need to be concerned.
The reasons for the excess risk of all-cause death and 
MACCE in ACS patients with diabetes/possible diabetes 
could be partially be explained [26–28], but some reasons 
are unexplained based on current analysis as the infor-
mation on anti-diabetic treatment was not available to 
our study. In our study, we observed that the in-hospital 
management for ACS was similar between patients with 
and without diabetes. However, anti-diabetic therapy in 
the acute phase is also very important for the prognosis 
of ACS patients with diabetes, and inappropriate hypo-
glycemic treatment could significantly increase the risk of 
death [29]. The guidelines have given clear anti-diabetic 
drug recommendations for patients with both CVD and 
diabetes [30, 31], and an increasing number of studies 
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have found that newer types of anti-diabetic drugs have a 
beneficial effect on lowering both blood glucose levels and 
risks of CVD, but conflicting results still exist [32–36]. In 
addition, the combined use of anti-diabetic drugs on car-
diovascular events should also be concerned [37]. Future 
studies should take this information into consideration.
Whether in the American, European, or other coun-
tries of the world, ACS patients with diabetes is common 
(usually greater than one-third of patients) and associ-
ated with a higher risk of death and other adverse events 
[2–5, 38]. Although studies have reported that the car-
diovascular outcomes of diabetes have been improved in 
recent years, number of people with diabetes still rises, 
the absolute burden of CVD will still be high [39]. Effec-
tive strategies to better manage the risk of these ACS 
patients with diabetes and improve their prognosis has 
always been the focus but also a challenge for cardiolo-
gists worldwide. In 2013, the European Society of Car-
diology in collaboration with the European Association 
for the Study of Diabetes developed the second guideline 
for diabetes, pre-diabetes, and cardiovascular diseases, 
which calls for physicians in the fields of cardiovascu-
lar medicine and diabetes to join forces to research and 
manage these conditions, given the close relationship 
between CVD and diabetes [30]. In 2015, the Chinese 
Society of Cardiology in collaboration with other socie-
ties also issued a guideline on the management of abnor-
mal glucose metabolism and CVD [40]. Following the 
efforts of both cardiologists and diabetologists, the risk 
of adverse events for ACS patients with diabetes/possible 
diabetes is expected to decrease [41].
Limitations
Some limitations of this study are worthy of mention. 
First, the results of OGTT during hospitalization were 
unavailable to this study, thus some diabetic patients 
may have been missed. However, OGTT was not rou-
tinely used in clinical practice, which future studies 
should take into consideration. Second, some patients 
with only increased FBG could not be definitively diag-
nosed with diabetes. However, using only tests for FBG 
revealed that at present, cardiologists do not pay suf-
ficient attention to the diagnosis of diabetes in ACS 
patients. Finally, as this was a real-world study for ACS 
patients based on medical records, limited information 
regarding diabetes was gathered, including incomplete 
data on body mass index as well as uncollected data 
on physical exercise information, diabetes types, and 
in-hospital anti-diabetic therapy. Some other interest 
points regarding diabetes, such as gender differences, 
different revascularization strategies, and regional 
impacts, still need more research in the future [42–44].
Conclusions
Our results showed that diabetes was highly preva-
lent among ACS patients in China. Considerable excess 
risk for early mortality and MACCE was found in ACS 
patients with diabetes. These findings highlight the 
importance of early detection and appropriate manage-
ment of diabetes in ACS patients, using specific therapies 
that have been demonstrated to improve outcomes.
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